Home / Conditions / Type 1 Diabetes / Liraglutide Plus Insulin for People with Type 1 Diabetes Improves Glycemic Control

Liraglutide Plus Insulin for People with Type 1 Diabetes Improves Glycemic Control

Jul 7, 2018
 

One-year, randomized study shows lower HbA1c, blood glucose, blood pressure, and body weight without significant increase in hypoglycemia.

Adults with type 1 diabetes (T1D) who take a daily dose of liraglutide demonstrated improvements in HbA1c levels, weekly average blood glucose levels and increased weight loss, according to the study, “Liraglutide as an Additional Treatment to Insulin in Patients with Type 1 Diabetes Mellitus—A 52-Week Randomized Double-Blinded Placebo-Controlled Clinical Trial,” presented today at the American Diabetes Association’s® (ADA’s) 78th Scientific Sessions®.

A prior study (Dandona, 2012) of daily liraglutide for 12 weeks indicated a positive impact on glycemic control, weight loss, and systolic blood pressure, therefore subsequent studies have been conducted.

This double-blind, placebo-controlled, randomized, one-year trial examined the effects of liraglutide on multiple health parameters in people with T1D. A total of 46 adults (average age 47.6 years) with T1D participated in the study. At the beginning of the trial, the patients had an average HbA1c level of 7.82, and an average body mass index of 28.9 Kg/m2. The patients were randomized, and 26 patients received daily injections of 1.8 mg of liraglutide, while 20 patients received daily injections of a placebo. Continuous glucose monitoring (CGM) was performed for four weeks before treatment and at the end of treatment.

At the completion of 52 weeks, the patients who had taken liraglutide showed improvements in blood glucose levels, weight, and blood pressure. The liraglutide group had a placebo-adjusted, average HbA1c decrease to 7.45 (p=0.009), and a weekly placebo-adjusted average blood glucose decrease from 174 to 156 mg/dl (p=0.021). There were no changes in reported incidences of hypoglycemia and no changes in percent of time spent below 70 mg/dl based on CGM, and the patients’ total insulin dose did not alter. Additionally, the liraglutide group had significant weight loss, from an average of 83.6 kg to 80.5 kg (p=0.01). Placebo-adjusted, average systolic blood pressure also decreased following liraglutide treatment, from 128 mmHg to 122 mmHg, while placebo-adjusted, diastolic blood pressure averages decreased from 79 mmHg to 75 mmHg.

Practice Pearls:

  • There was improvement in glucose levels when using liraglutide with insulin in people who have type 1 diabetes.
  • The patients who had taken liraglutide with insulin showed improvements in glucose levels, weight, and blood pressure.

ADA 78th Scientific Sessions, Orlando 2018